Global Blood Therapeutics Inc  

(Public, NASDAQ:GBT)    
Find more results for Deval L. Patrick´┐Ż

Officers and directors

Ted W. Love M.D.
President, Chief Executive Officer, Director
Hing Sham
Senior Vice President - Chemistry
John Schembri
Vice President of Finance and Administration
Peter Radovich
Vice President - Program Leadership and Business Strategy
Jung E. Choi
Chief Business and Strategy Officer
Eleanor L. Ramos M.D.
Chief Medical Officer
Charles J. Homcy M.D.
Kevin P. Starr
Willie L Brown Jr
Independent Director
Deval L. Patrick
Independent Director


400 E Jamie Ct Ste 101
United States - Map
+1-650-7417700 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Global Blood Therapeutics, Inc. is a biopharmaceutical company that engages in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is engaged in developing initial product candidate, GBT440, oral prophylactic therapy for sickle cell disease (SCD). The Company offers randomized, placebo-controlled, double-blind, single and multiple ascending dose Phase 1/2 clinical trial of GBT440 in healthy subjects and patients with SCD. It is also developing hemoglobin modifiers for pulmonary disorders, such as acute respiratory distress syndrome, in which increased oxygen delivery is needed. The Company, through its GBT440 or analog, also focuses on chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders and hereditary angioedema (HAE), which is in pre-clinical trials. In addition, the Company develops TBD, an oral kallikrein inhibitor, which are in Phase 1/2 clinical trials.

Related companies

* Delayed by up to 20 minutes -  Disclaimer